Nicotine Bitartrate Dihydrate: The Preferred Nicotine Form for Pouches and NRT

Every nicotine pouch on the market faces the same core engineering problem: deliver a precise dose of nicotine from a dry format, consistently, for 12+ months of shelf life. Nicotine bitartrate dihydrate solves that problem better than any alternative. That is why it has become the default nicotine form for the fastest-growing product category in the industry.

What It Is

Nicotine bitartrate dihydrate is a salt formed by combining pharmaceutical-grade freebase nicotine with L-tartaric acid. The compound crystallizes with two water molecules (the "dihydrate" part), producing a stable white crystalline powder with the molecular formula C₁₀H₁₄N₂·C₄H₆O₆·2H₂O and a molecular weight of approximately 462.4 g/mol.

The nicotine content is fixed at approximately 26.4% by weight. That number is not a range or an approximation. It is a stoichiometric fact of the molecule. When you weigh out 1 gram of bitartrate dihydrate, you know you have 264mg of nicotine. Every time. Compare that to working with liquid freebase nicotine, where concentration can drift over time due to oxidation and evaporation, and the precision advantage becomes obvious.

The crystalline structure also gives the compound a defined melting point (typically around 85 to 90°C), which serves as a quick identity check during incoming material inspection. If the melting point is off, something is wrong with the material before you even run a full assay.

Why It Wins on the Manufacturing Floor

Stability That Liquid Nicotine Cannot Match

Liquid freebase nicotine oxidizes. It degrades with light exposure. It discolors over time. You are fighting chemistry from the moment it leaves the supplier. Freebase nicotine at high purity starts as a nearly colorless liquid and can turn amber or brown within weeks if improperly stored. That degradation is not just cosmetic. Oxidized nicotine produces cotinine and nicotine-N-oxide, both of which affect the safety and efficacy profile of the finished product.

Nicotine bitartrate dihydrate in crystalline form resists all three degradation pathways under normal storage conditions. The salt form locks the nicotine molecule into a stable crystal lattice. Light, heat, and oxygen have a much harder time reaching the active compound. Accelerated stability studies consistently show less than 1% degradation over 24 months when stored at 25°C and 60% relative humidity in sealed containers.

That translates directly to longer product shelf life and less waste. For a manufacturer running tight margins on a high-volume SKU, the difference in scrap rates alone justifies the switch. One pouch manufacturer we work with reported cutting rejected batches by over 40% after switching from liquid nicotine to bitartrate dihydrate, primarily because they eliminated the variability introduced by nicotine degradation during storage.

Dosing Precision That Satisfies Regulators

The fixed 26.4% nicotine-to-salt ratio eliminates the variability that comes with liquid nicotine handling. Pipetting liquids introduces measurement uncertainty. Weighing powder does not. Any competent production line with a calibrated analytical balance can achieve ±0.1% accuracy on powder weights. Try getting that precision with a peristaltic pump dosing viscous liquid nicotine.

For pouch manufacturing, this matters at every scale. A 4mg pouch needs exactly 15.15mg of bitartrate dihydrate. The math is clean, the QC is simple, and the regulatory filing writes itself. When the FDA or a European notified body asks how you control nicotine content in your finished product, pointing to a gravimetric dosing process with a crystalline salt of defined composition is about as clean an answer as you can give.

The uniformity of the powder also matters for blend homogeneity. In pouch production, the nicotine source is blended with fillers (typically microcrystalline cellulose, hydroxypropyl cellulose, or similar), pH adjusters, flavorings, and humectants. A crystalline powder with consistent particle size distribution mixes more uniformly than a liquid sprayed onto a carrier. This reduces the coefficient of variation on nicotine content between individual pouches within a batch, which is a metric regulators pay close attention to.

Safer to Handle

Liquid nicotine at production concentrations is a dermal absorption hazard. At concentrations above 10%, accidental skin contact can produce symptoms of nicotine poisoning within minutes: nausea, elevated heart rate, headache, and in serious exposures, seizures. OSHA classifies nicotine as a hazardous substance, and EPA regulates it as an acute toxicity Category I compound.

Dry powder is significantly safer in a manufacturing environment. While inhalation precautions are still necessary, the risk of acute dermal absorption is dramatically lower with a crystalline solid than with a concentrated liquid. This reduces the cost and complexity of safety controls, simplifies storage (no secondary containment for liquid spills), and integrates directly into the dry-mix processes that pouch production lines already use.

For facilities that need to meet GMP and ISO requirements, the risk assessment for handling bitartrate dihydrate powder is substantially simpler than for liquid nicotine. That means faster facility qualifications and fewer regulatory hurdles during site inspections.

Fast Dissolution Where It Counts

The dihydrate form dissolves readily in water. Solubility exceeds 200 g/L at 25°C, which is well above what any oral nicotine product requires. When a pouch contacts saliva, the bitartrate releases nicotine efficiently for absorption through the oral mucosa. Good solubility means the user gets a consistent experience from the first minute to the last.

The dissolution rate is also relevant. Because the dihydrate form already contains water of crystallization, it does not need to hydrate before dissolving. This gives it a faster dissolution onset compared to anhydrous nicotine salts, which can be a meaningful differentiator in consumer experience testing.

Applications Beyond Pouches

Lozenges

The defined nicotine content and water solubility make bitartrate dihydrate a natural fit for lozenges where controlled dissolution and consistent dosing are non-negotiable. Lozenge formulations typically target 1mg, 2mg, or 4mg nicotine per unit. With bitartrate dihydrate, the calculation is straightforward and the weight tolerance on each lozenge directly translates to a predictable nicotine dose. Nicotine polacrilex remains the standard for gum-based NRT, but for lozenges, bitartrate dihydrate is gaining share because of its simpler formulation requirements.

Nicotine Gums

The crystalline form distributes uniformly within a gum matrix. Pharmaceutical-grade material meets the stringent purity requirements for NRT products. While polacrilex resin-based systems dominate the commercial gum market (and are specifically described in pharmacopoeia monographs), some newer formulations are exploring bitartrate dihydrate as an alternative active ingredient, particularly for products targeting markets outside the traditional NRT channel.

Sublingual Tablets

An emerging NRT format that benefits from the compound's rapid dissolution and predictable release profile. Sublingual delivery bypasses first-pass metabolism, improving bioavailability. The fast dissolution of bitartrate dihydrate in a small volume of saliva makes it well-suited for this application, and several clinical-stage NRT programs are using it as the nicotine source.

Research and Analytical Standards

Bitartrate dihydrate is also widely used as a reference standard in analytical chemistry. Its defined stoichiometry and high purity make it suitable for preparing nicotine calibration standards, which are essential for HPLC and GC methods used in quality control across the industry.

The global pouch market is the primary growth driver, but the same properties that make bitartrate dihydrate ideal for pouches apply across oral nicotine products. As nicotine salt formulations continue to diversify, the bitartrate form is increasingly the starting point for product development.

Quality Specifications

Pharmaceutical-grade nicotine bitartrate dihydrate should meet:

• Purity: 99.0% minimum (dried basis)
• Nicotine content: 26.0-27.0% (calculated as nicotine)
• Water content: 10.0-12.0% (Karl Fischer)
• Heavy metals: Within USP/EP pharmacopoeial limits (Pb less than 10 ppm, As less than 3 ppm, Cd less than 1 ppm, Hg less than 1 ppm)
• Residual solvents: Compliant with ICH Q3C guidelines
• Specific optical rotation: Consistent with L-nicotine hydrogen tartrate
• Particle size distribution: Specified per application (pouches typically require D90 below 250 microns)
• Microbial limits: Total aerobic count below 1000 CFU/g, yeast and mold below 100 CFU/g

For EU manufacturers operating under the TPD or US manufacturers subject to FDA oversight, every shipment needs batch-specific COAs and full chain-of-custody documentation. An STC-certified supplier is not a nice-to-have. It is a procurement requirement. The difference between a supplier who provides template COAs and one who provides batch-specific analytical data is the difference between a smooth regulatory filing and a deficiency letter.

Storage and Handling Best Practices

Nicotine bitartrate dihydrate is hygroscopic. Improper storage can cause caking, clumping, and degradation. Keep these guidelines in mind:

• Store at 15-25°C in a dry environment (below 60% RH)
• Keep containers sealed when not in active use
• Use nitrogen blanketing for long-term storage of bulk quantities
• Rotate stock on a first-in, first-out basis
• Protect from direct light, even though the crystalline form is more light-stable than liquid nicotine

What to Ask Your Supplier

Are they providing batch-specific COAs with full analytical data? Can they show complete chain of custody from tobacco source to finished product? Are they manufacturing under ISO 9001, HACCP, and GMP conditions? Can they scale with you as your production ramps? Do they have USP/EP grade nicotine as the starting material for their salt synthesis?

If any answer is no, you are taking on risk that will surface at the worst possible time: during a regulatory audit or a customer complaint investigation.

NicAlliance supplies pharmaceutical-grade nicotine bitartrate dihydrate with STC traceability, batch-specific COAs, and the technical support to help you get your formulation right the first time. Request a quote and our team will respond within 24 hours.

Frequently Asked Questions